The SARS-CoV-2 pandemic has presented the field of infectious diseases and the clinical trials networks with a number of challenges and opportunities. This Administrative Supplement request is being submitted for the parent grant, the Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit (Columbia Partnership Clinical Trials Unit, grant # 5UM1AI069470). The Columbia Partnership CTU encompasses four Clinical Research Sites (CRSs) and one protocol-specific CRS aligned with three DAIDS-sponsored networks, but this request is focused exclusively to support a crucial activity, the efficient and rapid expansion of SARS- CoV-2 serological and molecular testing in diverse communities served by three of the four CRSs: The Columbia P&S CRS, Harlem Prevention Center CRS and Bronx Prevention Center CRS. Each of the CRSs, by virtue of their location in areas highly impacted by COVID-19 disease, relationships with local communities, clinical and scientific expertise of investigators is in a unique position to not only expand testing, but do so by using innovative strategies and among populations at greatest risk of the disease.
The specific aims of this supplement request are: (1) To leverage the existing clinical, laboratory and administrative infrastructure of the Columbia Partnership CTU to efficiently and rapidly scale-up for SARS-CoV-2 testing activities; specifically to help scale up testing in response to the growing need to provide clinical testing to diverse communities heavily and disproportionately impacted by COVDI-19; and to prepare for upcoming clinical trials investigating therapeutic and preventive interventions for COVID-19 disease. (2) To build on the existing community engagement infrastructure to implement innovative methods to engage local communities and stakeholders around SARS-CoV-2 testing and research efforts and to develop a suite of educational materials in support of COVID-19 studies.

Public Health Relevance

Access to SARS-CoV-2 testing is one of the highest global health priorities. This project seeks to build on the expertise of the Columbia Partnership CTU to expand SARS-CoV-2 testing in diverse communities most impacted by COVID-19.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
3UM1AI069470-14S1
Application #
10169016
Study Section
Program Officer
Pouliot, Eileen M
Project Start
2020-06-10
Project End
2020-11-30
Budget Start
2020-06-10
Budget End
2020-11-30
Support Year
14
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Justman, Jessica E; Nair, Gonasagrie Lulu; Hendrix, Craig W et al. (2018) Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. J Acquir Immune Defic Syndr 78:175-182
Fong, Youyi; Shen, Xiaoying; Ashley, Vicki C et al. (2018) Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. J Infect Dis 217:1280-1288
Tieu, Hong-Van; Laeyendecker, Oliver; Nandi, Vijay et al. (2018) Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City. PLoS One 13:e0200269
Yang, Cui; Latkin, Carl; Tobin, Karin et al. (2018) An Event-Level Analysis of Condomless Anal Intercourse with a HIV-Discordant or HIV Status-Unknown Partner Among Black Men Who Have Sex with Men from a Multi-site Study. AIDS Behav 22:2224-2234
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Mitchell, Kate M; Dimitrov, Dobromir; Hughes, James P et al. (2018) In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs? AIDS 32:809-818
Meyers, Kathrine; Rodriguez, Kristina; Brill, Atrina L et al. (2018) Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants. AIDS Behav 22:1209-1216
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Figueroa, Dominique B; Tillotson, Joseph; Li, Maoji et al. (2018) Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. PLoS One 13:e0195764
Franks, Julie; Hirsch-Moverman, Yael; Loquere Jr, Avelino S et al. (2018) Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study. AIDS Behav 22:1139-1149

Showing the most recent 10 out of 122 publications